NCT03076164View on ClinicalTrials.gov

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

December 18, 2020

Study Completion Date

December 18, 2020

Conditions
Lung AdenocarcinomaLung CancerLung Cancer MetastaticLung Cancer Stage IVRecurrent Lung AdenocarcinomaRecurrent Lung Cancer
Interventions
DRUG

Trametinib

Trametinib 1.5mg once daily by mouth

DRUG

Erlotinib

Erlotinib 75mg once daily by mouth

Trial Locations (7)

10021

Memorial Sloan Kettering Cancer Center, New York

10604

Memoral Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

07920

Memoral Sloan Kettering Cancer Center, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03076164 - A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | Biotech Hunter | Biotech Hunter